Product Overview
The SirPlux Duo Drug-Coated Balloon is powered by an innovative drug delivery platform. Our DCB achieves long-term drug retention in tissue and leaves no implant behind.
Improved Restenosis Prevention
Nanoparticle drug delivery provides sustained drug release and retention in tissue, resulting in stent-like patency and restenosis prevention.
Higher Potency with Less Drug
Uses lower doses of Sirolimus and Paclitaxel to achieve same antiproliferative effects than with each drug separately1.
Nothing Left Behind
Preserves long-term arterial health with no risk of late stent thrombosis.
Positive Health Economics
SirPlux Duo is designed to be less expensive than stent-based coronary treatments, both as a device and as a procedure. It may also lower the cost of re-intervention options.
Nanotechnology Benefits
A.N.T.’s proprietary nanotechnology opens the way for more effective endovascular and cardiovascular treatments. SirPlux Duo delivers drugs using 100% biodegradable nanoparticles, deployed directly to the target site.
Our DCB relies on drug-agnostic nanoparticles. These can be adapted to deliver any treatment to any blood vessel, which creates the possibility of novel non-invasive treatments to a host of other conditions.
Unique Competitive Advantages
Competing DCBs and DESs
Drug Delivery and Impact
Delivers two synergistic antiproliferative drugs
Deliver only one antiproliferative drug with limited effects
No flaking or loss of drug during handling and delivery
Significant risk of emboli from flaking
Slow & sustained in-tissue delivery
Low-efficiency, out-of-tissue delivery
12x less SRL and 1.7x less PTX to achieve the same effects
High dosage for inhibiting growth, leading to higher toxicity
Clinical Outcome
Up to 5x lower neointimal growth
Up to 45x less cell proliferation
Noteworthy tissue growth and cell proliferation
1. Data on file at ANT.
2. Bench testing of Philips StellarexTM DCB, BD LutonixTM DCB, and SirPlux Duo DCB. Data on file at ANT.
Unique Competitive Advantages
Drug Delivery and Impact
Delivers two synergistic antiproliferative drugs
Risks During Handling
No flaking or loss of drug during handling and delivery
Drug Retention
Slow & sustained in-tissue delivery
API Dosage
12x less SRL and 1.7x less PTX to achieve the same effects
Clinical Outcome
Up to 45x less cell proliferation
Competing DCBs and DESs
Drug Delivery and Impact
Deliver only one antiproliferative drug with limited effects
Risks During Handling
Significant risk of emboli from flaking
Drug Retention
Low-efficiency, out-of-tissue delivery
API Dosage
High dosage for inhibiting growth, leading to higher toxicity
Clinical Outcome
Noteworthy tissue growth and cell proliferation
1. Data on file at ANT.
2. Bench testing of Philips StellarexTM DCB, BD LutonixTM DCB, and SirPlux Duo DCB. Data on file at ANT.